VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

VST-Bio-Corp-study-UK

More Like This

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

PR Newswire associated0

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

PR Newswire associated0

A major advance on stroke at Montpellier University Hospital published in the New England Journal of Medicine

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

PR Newswire associated0

Brainomix Announces New Studies Further Validating the Impact of Brainomix 360 Stroke Platform

Exidavnemab phase 2a study expanded to include MSA patients

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis